Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The chronic progressive decline in lung function observed in idiopathic pulmonary fibrosis (IPF) appears to result from persistent nonresolving injury to the epithelium, impaired restitution of the epithelial barrier in the lung, and enhanced fibroblast activation. Thus, understanding these key mechanisms and pathways modulating both is essential to greater understanding of IPF pathogenesis. We examined the association of VEGF with the IPF disease state and preclinical models in vivo and in vitro. Tissue and circulating levels of VEGF were significantly reduced in patients with IPF, particularly in those with a rapidly progressive phenotype, compared with healthy controls. Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice. In vitro, apoptotic endothelial cell-derived mediators enhanced epithelial cell injury and reduced epithelial wound closure. This process was rescued by VEGF pretreatment of the endothelial cells via a mechanism involving thrombospondin-1 (TSP1). Taken together, these data indicate beneficial roles for VEGF during lung fibrosis via modulating epithelial homeostasis through a previously unrecognized mechanism involving the endothelium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Standardized Quantification of Pulmonary Fibrosis in Histological Samples
Hübner, R.-H., Gitter, W., Eddine El Mokhtari, N., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., & Bewig, B. (2008) · BioTechniques · doi:10.2144/000112729 · Cited by 817 · cited 1×
“The extent of lung remodeling was quantified using a minor modification of the Modified Ashcroft Scoring system (65), as we have previously described (64).”
MethodLiang, J., Zhang, Y., Xie, T., Liu, N., Chen, H., Geng, Y., Kurkciyan, A., Mena, J. M., Stripp, B. R., Jiang, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4192 · Cited by 287 · cited 1×
“Given the emerging role of TLR4 in mediating epithelial injury and repair responses (58), because TSP1 serves as a danger-associated signal for TLR4 (59), our data suggest”
BackgroundZhou, Y., Peng, H., Sun, H., Peng, X., Tang, C., Gan, Y., Chen, X., Mathur, A., Hu, B., Slade, M. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007096 · Cited by 215 · cited 1×
“FACS-based enumeration of VEGF receptor expression was performed on lung tissues that had been digested and processed, as we have previously described (63).”
MethodSelf-citationExploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Natural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191 · cited 1×
“For example, some patients exhibit only a gradual decline in forced vital capacity (FVC) and may live for many years following diagnosis (2), while others suffer a more progressive clinical course characterized by rapid physiologic decline and death.”
BackgroundInfluentialA Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis
Bauer, Y., Tedrow, J., de Bernard, S., Birker-Robaczewska, M., Gibson, K. F., Guardela, B. J., Hess, P., Klenk, A., Lindell, K. O., Poirey, S., et al. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0310oc · Cited by 182
Cited by
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
Self-citationSavin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Metadata
- Authors
- Murray, L. A., Habiel, D. M., Hohmann, M., Camelo, A., Shang, H., Zhou, Y., Coelho, A. L., Peng, X., Gulati, M., Crestani, B., Sleeman, M. A., Mustelin, T., Moore, M. W., Ryu, C., Osafo-Addo, A. D., Elias, J. A., Lee, C. G., Hu, B., Herazo-Maya, J. D., Knight, D. A., Hogaboam, C. M., & Herzog, E. L.
- Venue
- JCI Insight
- Published
- 2017-08-17
- Volume
- 2
- Issue
- 16
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2748216636
- Cited by
- 85
- References
- 11
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. https://app.cochat.ai/papers/10.1172/jci.insight.92192
- The paper
- Murray, L. A., Habiel, D. M., Hohmann, M., Camelo, A., Shang, H., Zhou, Y., Coelho, A. L., Peng, X., Gulati, M., Crestani, B., Sleeman, M. A., Mustelin, T., Moore, M. W., Ryu, C., Osafo-Addo, A. D., Elias, J. A., Lee, C. G., Hu, B., Herazo-Maya, J. D., . . . Herzog, E. L. (2017). Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight. https://doi.org/10.1172/jci.insight.92192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.